CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
Now revised and updated, explore CADTH’s free online resource for grey literature searching, “Grey Matters: a practical tool for searching health-related grey literature.”
Grey Matters: a practical tool for searching health-related grey literature
In order to use the tool:
save file
open file
“Open as read only?” will appear
...
News and Events CADTH’s 2020 Virtual Symposium: A Success! CADTH successfully wrapped up our first-ever virtual Symposium that was held on November 9 and 10, 2020. With more than 1,500 people in attendance, a diverse group of stakeholders gathered to discuss health care decision-making in an age of uncertainty, with health technology expert...
We are pleased to announce the appointment of Brent Fraser to the position of Vice-President, Pharmaceutical Reviews, effective August 4, 2015. In this role, Brent will be responsible for the CADTH Common Drug Review, the pan-Canadian Oncology Drug Review, and all other aspects of CADTH work in the pharmaceutical space. Brent joins CADTH from t...
The 2017 CADTH Symposium will feature another outstanding roster of Canadian and international experts, thought-provoking plenary sessions, educational workshops, and insightful panel, oral, and poster presentations. We’re coming back to Ottawa so you can also enjoy the history and pageantry of the year-long celebration of Canada’s 150th anniv...
News and Events CADTH Recommends First Gene Therapy Treatment for Rare Form of Childhood Vision Loss On November 16, CADTH recommended that Canada’s federal, provincial, and territorial drug plans (except Quebec) should reimburse, with conditions, voretigene neparvovec (also known as Luxturna and licensed by Novartis Pharmaceutical...
News and Events “There’s Always Evidence…” — A Special Three-Part Webinar January and February 2021 Systematic reviews and meta-analyses are regarded as the gold standard for evidence, but they are not always readily available to inform a specific clinical, policy, or health management decision. In this special three-part webinar serie...
EVIDENCE FOR EVERYONE Expanding the Reach of Health Technology Assessment Initially established as a tool for policy-makers, health technology assessment (HTA) now supports a much broader range of decision-makers. Everyone — whether technology developers in academic settings and industry, patients, clinicians, regional health authority and hos...